<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210423051054N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-11</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of exosomes in the treatment of knee osteoarthritis</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of therapeutic effect of placental mesenchymal stem cell exosome injection in improving clinical symptoms and MRI changes in patients with knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/55913</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this clinical trial study, 30 patients with bilateral osteoarthritis of the knee, referred to the physical medicine and rehabilitation clinic of Taleghani Hospital in Tehran, will be randomly entered into the study. Random Allocation software will be used for random assignment of samples. Random sequences from 1 to 30 will be created using this software. Random allocation concealment method will be used for hiding. In this way, the created sequences are recorded on cards and these cards will be placed in sealed envelopes. Then, according to the order of entry of eligible people to study, each envelope will be opened and their assigned number will be determined. Thus, if the desired number was even, the right knee will be selected as the intervention and the left knee as the control, and if the desired number is odd, the left knee will be selected as the intervention and the right knee as the control, Blinding description: According to the codings performed for patients and drugs, all patients, caregivers, data collector, people who evaluate the outcomes, as well as data analyzer, for the intervention performed in each patient (drug or Placebo) are unaware. Both knees of the patient are injected. Drug is injected in one knee and placebo in the other, randomly.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Injection of 5 cc of placental mesenchymal stem cell exosome into the knee with anterolateral approach in the flexed position, isometric strengthening exercises for quadriceps, adductor and abductor muscles of the thigh (10 times and each time for 10 seconds), 2 times a day, and stretching of hamstrings (3 times and each time for 30 seconds), 2 times a day. Intervention 2: Control group: Injection of 5 cc of normal saline into the knee with anterolateral approach in the flexed position, isometric strengthening exercises for quadriceps, adductor and abductor muscles of the thigh (10 times and each time for 10 seconds), 2 times a day, and stretching of hamstrings (3 times and each time for 30 seconds), 2 times a day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rasa Salmani Oshnari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shohadaye Tajrish Hospital, Shahrdari St, Tajrish Sq</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1989934148</zip>
        <telephone>+98 21 25719</telephone>
        <email>rasa_salmani@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Najmeh Sadat Bolandnazar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taleghani Hospital, Yaman St, Shahid Chamran Hwy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1115119857</zip>
        <telephone>+98 21 2243 2560</telephone>
        <email>n.sadat.bolandnazar@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pain in both knees over the past 6 months, which is related to the degenerative process of the knee, requires pain medication and has lasted for more than a month.
Graphical confirmation of bilateral knee osteoarthritis with grade 2 or 3 based on the Kellgren-Lawrence classification.
The knee pain intensity should be greater than or equal to 4 according to the VAS.</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Younger than 45 years or older than 65 years
Rheumatic or collagen vascular disease
History of malignancy
Coagulopathy or taking anticoagulant drug
Any injection into the knee joint during the last 3 months
A history of recent severe knee trauma in the past 1 month
Septic arthritis of the knee or active wound of the knee joint
Genovarum or genovalgum greater than 20 degrees
Total knee replacement
Cardiac pacemaker
Cochlear implantation
Existence of fragments or foreign metal object in the knee or around the arteries, nerves and brain</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bilateral primary osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Injection of 5 cc of placental mesenchymal stem cell exosome into the knee with anterolateral approach in the flexed position, isometric strengthening exercises for quadriceps, adductor and abductor muscles of the thigh (10 times and each time for 10 seconds), 2 times a day, and stretching of hamstrings (3 times and each time for 30 seconds), 2 times a day.</i_keyword>
      <i_keyword>Control group: Injection of 5 cc of normal saline into the knee with anterolateral approach in the flexed position, isometric strengthening exercises for quadriceps, adductor and abductor muscles of the thigh (10 times and each time for 10 seconds), 2 times a day, and stretching of hamstrings (3 times and each time for 30 seconds), 2 times a day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: Before intervention, 2 and 6 months after intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Pain intensity, stiffness, and physical activity. Timepoint: Before intervention, 2 and 6 months after intervention. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index.</prim_outcome>
      <prim_outcome>Pain or discomfort, maximum distance walked, and activities of daily living. Timepoint: Before intervention, 2 and 6 months after intervention. Method of measurement: Lequesne Index.</prim_outcome>
      <prim_outcome>Patellofemoral cartilage volume. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Tibiofemoral cartilage volume. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Knee joint synovitis. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Medial and lateral meniscus disintegration. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Patellofemoral cartilage erosion. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Tibiofemoral cartilage erosion. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
      <prim_outcome>Anterior cruciate ligament  injury. Timepoint: Before intervention and 6 months after intervention. Method of measurement: Magnetic resonance imaging.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-03-08</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti University of Medical Sciences, Yaman St, Shahid Chamran Hwy Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
